Prognostic and clinicopathological significance of long noncoding RNA H19 overexpression in human solid tumors: evidence from a meta-analysis.
Many studies have reported that the expression level of lncRNA H19 was increased in various tumors. LncRNA H19 may play a significant role in cancer occurrence and development. An increased level of H19 was also associated with poor clinical outcomes of cancer patients.



12 eligible studies were screened, with a total of 1437 cancer patients. From the results of meta-analysis, as for prognosis, the patients with high expression of lncRNA H19 were shorter in OS (HR=1.08, 95% CI: 1.05-1.12). Statistical significance was also showed in subgroup meta-analysis stratified by the cancer type, analysis type and sample size. In addition, the patients detected with high H19 expression may be poorer in DFS (HR=1.27; 95% CI = 0.97-1.56). As for clinicopathology, it showed that increased H19 was related to poor histological grades (OR=2.31, 95% CI: 1.12-4.75), positive lymph node metastasis (OR=2.29, 95 % CI: 1.21-4.34) and advanced clinical stage (OR=4.83, 95% CI: 3.16-7.39).



Eligible studies were collected by retrieving keywords in PubMed, Web of Science, Embase, CNKI and Wanfang database, from 1966 to April 23, 2016. This quantitative meta-analysis was performed with Stata SE12.0 and RevMan5.3 software. It aimed to explore the association between H19 expression level and prognosis and clinicopathology.



LncRNA-H19 may be a novel molecular marker for predicting solid tumors. It can also be a predictive factor of clinicopathological features in various cancers. Further studies are needed to verify the clinical utility of H19 in human cancers.
Department of General Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi Province, P. R. China.
Fang-teng
FT
Liu
Department of General Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi Province, P. R. China.
Hua
H
Pan
Department of General Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi Province, P. R. China.
Guang-feng
GF
Xia
Department of General Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi Province, P. R. China.
Cheng
C
Qiu
Department of General Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi Province, P. R. China.
Zheng-ming
ZM
Zhu
D014408:Biomarkers, Tumor / Q000235:genetics*; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D015972:Gene Expression Regulation, Neoplastic; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008207:Lymphatic Metastasis; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009369:Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016017:Odds Ratio; D010641:Phenotype; D062085:RNA, Long Noncoding / Q000235:genetics*; D012307:Risk Factors; D013997:Time Factors; D047368:Tumor Burden; D015854:Up-Regulation
D014408:Biomarkers, Tumor; C094335:H19 long non-coding RNA; D062085:RNA, Long Noncoding
H19; carcinoma; long noncoding RNA; meta-analysis; prognosis